Literature DB >> 17450095

Minimally invasive percutaneous nephrolithotomy for staghorn calculi: a novel single session approach via multiple 14-18Fr tracts.

Zeng Guohua1, Wen Zhong, Xun Li, Kaijun Wu, Wenzhong Chen, Ming Lei, Zhaohui He.   

Abstract

OBJECTIVE: To report our experience with minimally invasive percutaneous nephrolithotomy (MPCNL) (14-18Fr percutaneous tract) to treat staghorn calculi via multiple percutaneous tracts in a single session procedure, and evaluate the feasibility and efficiency of this technique. PATIENTS AND METHODS: From March 2001 to November 2005, 100 patients with staghorn calculi were treated by MPCNL via multiple percutaneous tracts. The size and location of the stone, operative parameters, number of tracts, stone-free rate, operating time, hospital stay, and complications were analyzed retrospectively.
RESULTS: A total of 209 percutaneous tracts were established in 100 renal units during 128 operations including 28 second-look procedures. The mean operating time was 107 minutes (range 43 to 130 min) and the mean hospital stay was 9.4 days (range 6 to 13 d). The initial stone clearance rate of 72% after the first session was improved to 93% after a second-look procedure in 28 patients. The mean blood loss was 112 mL (range 64 to 483 mL), 3 patients required blood transfusion and 1 patient with branched renal arterial injury during puncture received a highly elective embolism. Seven patients had a postoperative fever of 38.5 degrees C or greater, whereas 4 patients had mild hydropneumothorax.
CONCLUSIONS: With the development of instrument and increased experience, judiciously made multiple percutaneous tracts in a single session MPCNL for treating staghorn calculi in selected cases is safe, feasible, and efficient with an acceptable morbidity.

Entities:  

Mesh:

Year:  2007        PMID: 17450095     DOI: 10.1097/SLE.0b013e318038faa4

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  7 in total

1.  Is standard percutaneous nephrolithotomy still the standard treatment modality for renal stones less than three centimeters?

Authors:  Ömer Sarılar; Faruk Özgör; Onur Küçüktopçu; Burak Uçpınar; Mehmet Fatih Akbulut; Metin Savun; Zafer Gökhan Gürbüz; Murat Binbay
Journal:  Turk J Urol       Date:  2017-05-03

2.  Percutaneous nephrolithotomy in patients with scoliosis: our institutional experience.

Authors:  He Qun Chen; Feng Zeng; Lin Qi; Yuan Li
Journal:  Urolithiasis       Date:  2013-01-05       Impact factor: 3.436

3.  Minimally invasive percutaneous nephrolithotomy for simple and complex renal caliceal stones: a comparative analysis of more than 10,000 cases.

Authors:  Guohua Zeng; Zhijian Zhao; ShawPong Wan; Zanlin Mai; Wenqi Wu; Wen Zhong; Jian Yuan
Journal:  J Endourol       Date:  2013-10       Impact factor: 2.942

4.  Comparison of standard- and mini-percutaneous nephrolithotomy for staghorn stones.

Authors:  Sanjay Khadgi; Ahmed R El-Nahas; Mohamed El-Shazly; Abdullatif Al-Terki
Journal:  Arab J Urol       Date:  2021-01-21

5.  Chinese minimally invasive percutaneous nephrolithotomy for intrarenal stones in patients with solitary kidney: a single-center experience.

Authors:  Zhichao Huang; Fajun Fu; Zhaohui Zhong; Lei Zhang; Ran Xu; Xiaokun Zhao
Journal:  PLoS One       Date:  2012-07-10       Impact factor: 3.240

6.  A comparison of supracostal and infracostal access approaches in treating renal and upper ureteral stones using MPCNL with the aid of a patented system.

Authors:  Difu Fan; Leming Song; Donghua Xie; Min Hu; Zuofeng Peng; Xiaohui Liao; Tairong Liu; Chuance Du; Lunfeng Zhu; Lei Yao; Jianrong Huang; Zhongsheng Yang; Shulin Guo; Wen Qin; Jiuqing Zhong; Zhangqun Ye
Journal:  BMC Urol       Date:  2015-10-13       Impact factor: 2.264

7.  Single- versus Multiple-Tract Percutaneous Nephrolithotomy in the Surgical Management of Staghorn Stones or Complex Caliceal Calculi: A Systematic Review and Meta-analysis.

Authors:  Binbin Jiao; Zhenshan Ding; Zhenkai Luo; Shicong Lai; Xin Xu; Xing Chen; Guan Zhang
Journal:  Biomed Res Int       Date:  2020-12-17       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.